AMGEN

Analysis of Amgen share price

BUY   SELL
72% of retail investor accounts lose money when trading CFDs with this provider.
 
Chart provided by Tradingview

The pharmaceutical and biotech sector is probably one of the most closely followed areas of activity on the stock markets today. This is why we have decided to talk to you about a very popular and highly liquid American stock, namely Amgen. Here you will discover the precise activity of this company and some data concerning the analysis of its prices during the last ten years from the different historical stock charts.

Elements that can influence the price of this asset:

Analysis N°1

First, the development of new, as yet untreated, life-threatening diseases may allow Amgen to offer new treatments and thus boost its growth.

Analysis N°2

The group is currently making efforts to position itself in the emerging markets of Asia and Africa. The first results of these investments will be closely monitored.

Analysis N°3

Of course, the technological innovations from which the group benefits and which it develops itself are also to be followed with the greatest attention.

Analysis N°4

We will keep a close eye on the various government regulations regarding the reimbursement of certain treatments, which may have a direct impact on the Amgen group's sales capabilities.

Analysis N°5

The same applies to the tightening of regulations for the licensing of new treatments in the United States and the rest of the world.

Analysis N°6

Finally, we will also keep an eye on the expiration of patents currently held by Amgen and on the arrival on the market of competing treatments.

72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500

General presentation of Amgen

The American group Amgen is currently one of the world's leading biotechnology companies. Its business consists mainly of selling drugs for the treatment of cancer, metabolic disorders, bone diseases and other health problems. It also earns royalties for about 4% of its profits.

The vast majority of this company's sales are in the United States (76%)

Amgen's share price is currently listed on the Nasdaq Select Global Market. It is therefore included in the calculation of the Nasdaq stock index.

Analysis of Amgen share price
72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500

The major competitors of Amgen

To further your knowledge of the company and Amgen stock, here is a quick overview of its main competitors in the industry:

Pfizer 

First of all, the Pfizer Group, which operates in 150 countries, is one of the leaders in its sector in terms of sales and market capitalization. It employs nearly 81,800 people worldwide.

Sanofi 

Another major competitor of Amgen is the French group Sanofi which is a transnational company active in the field of pharmaceuticals and vaccines.

Roche 

Still among the main competitors of the Amgen group, we must take into account the Roche company which is a Swiss pharmaceutical company and one of the leaders in this sector worldwide. Roche is both specialized in the pharmaceutical sector but also in the diagnostic sector. For some years now, it has been focusing on the segment of individualized medicine and operates in almost 150 countries around the world with a payroll of 94,000 employees.

Merck 

We will also follow closely the data and news of the German group Merck which was founded in 1668 and which operates in several different fields including that of pharmaceuticals and chemicals. It is based in Darmstadt in the state of Hesse.

Novartis 

Finally, we will keep an eye on the Novartis Pharmaceutical Group which is a Swiss company created in 1996 following the merger between Ciba-Geigy and Sandoz and which has its headquarters in Basel, Switzerland.


The major partners of Amgen

Serono

In 2002, the Amgen group and the Swiss group Serono announced a licensing and sales agreement allowing Serono to sell Novantrone, developed by Amgen in the United States.

Novartis

In 2015, Amgen and its competitor Novartis announced a cooperation agreement in the field of neurological treatments and in particular regarding the development and commercialization of a treatment for Alzheimer's disease.

Servier

In 2016, it was the Servier group that signed a collaboration agreement with Amgen in the field of cardiovascular disease treatments. Servier will be able to market Omecamtiv Mecabril for heart failure in Europe and Russia in exchange for a $10 million payment to Amgen.

72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500

Frequently Asked Questions

What are Amgen's flagship products?

The Amgen group already holds several patents in connection with the drugs it has brought to market, including: Epogen against anemia, Aranesp against anemia, Sensipar Mimpara against secondary hyperparathyroidism, Enbrel against psoriasis and rheumatoid arthritis, Neupogen against netropenia, Nelasta against netropenia, Nplate against thrombocytopenia, Vectibix for metastatic colorectal cancer, Prolia for osteoporosis, XGEVA for bone metastases, Kyprolis for multiple myeloma, Repatha for hypercholesterolemia, Imlygic for metastatic melanoma.

Who are the main shareholders of the Amgen group today?

Amgen Group's current major shareholders are Capital Research & Management at 11.9%, The Vanguard Group at 8.02%, Capital Research & Management Global at 4.93%, SSgA Funds Management at 4.45%, Fidelity Management & Research at 3.34%, PRIMECAP Management at 3.11%, BlackRock Fund Advisors at 2.66%, NWQ Investment Management at 1.96%, Putnam at 1.84% and Geode Capital Management at 1.63%.

On which market is Amgen stock listed?

The Amgen Group's shares are currently listed on the American Nasdaq market in New York. Moreover, we know that this company is part of the composition of the benchmark Nasdaq 100 stock index, which lists the 100 largest-capitalized American and international companies in this sector and in the technology sector. This gives us a better idea of this company's market weight.

72% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. This is an advert for trading CFDs on Plus500